Related Experiment Video
Updated: May 17, 2026
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
Limiting spinal cord injury by pharmacological intervention
John V Priestley1, Adina T Michael-Titus, Wolfram Tetzlaff
1Queen Mary University of London, London, UK. j.v.priestley@qmul.ac.uk
Abstract:
The direct primary mechanical trauma to neurons, glia and blood vessels that occurs with spinal cord injury (SCI) is followed by a complex cascade of biochemical and cellular changes which serve to increase the size of the injury site and the extent of cellular and axonal loss. The aim of neuroprotective strategies in SCI is to limit the extent of this secondary cell loss by inhibiting key components of the evolving injury cascade. In this review we will briefly outline the pathophysiological events that occur in SCI, and then review the wide range of neuroprotective agents that have been evaluated in preclinical SCI models. Agents will be considered under the following categories: antioxidants, erythropoietin and derivatives, lipids, riluzole, opioid antagonists, hormones, anti-inflammatory agents, statins, calpain inhibitors, hypothermia, and emerging strategies. Several clinical trials of neuroprotective agents have already taken place and have generally had disappointing results. In attempting to identify promising new treatments, we will therefore highlight agents with (1) low known risks or established clinical use, (2) behavioral data gained in clinically relevant animal models, (3) efficacy when administered after the injury, and (4) robust effects seen in more than one laboratory and/or more than one model of SCI.
Insights
Spinal cord injury (SCI) triggers secondary damage. This review examines neuroprotective agents to limit cell loss, focusing on promising treatments for future clinical trials.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Pharmacology
Background:
- Spinal cord injury (SCI) involves primary mechanical trauma followed by secondary biochemical and cellular damage, exacerbating neuronal and axonal loss.
- Neuroprotective strategies aim to mitigate this secondary injury cascade and preserve tissue integrity.
Purpose of the Study:
- To review neuroprotective agents investigated in preclinical spinal cord injury models.
- To identify promising therapeutic candidates based on safety, efficacy in relevant models, and post-injury administration potential.
Main Methods:
- Outline pathophysiological events following SCI.
- Categorize and review various neuroprotective agents, including antioxidants, erythropoietin, lipids, riluzole, opioid antagonists, hormones, anti-inflammatory drugs, statins, calpain inhibitors, and hypothermia.
- Evaluate agents based on risk profile, clinical relevance, post-injury efficacy, and reproducibility across studies.
Main Results:
- A wide array of neuroprotective agents have been tested in SCI models.
- Clinical trials of neuroprotective agents have yielded generally disappointing outcomes.
- Criteria for promising agents include low risk, clinical relevance, post-injury efficacy, and robust, reproducible effects.
Conclusions:
- Identifying effective neuroprotective agents for SCI remains a significant challenge.
- Future research should prioritize agents meeting specific criteria for clinical translation.
- Further investigation into promising candidates is crucial for developing effective SCI treatments.
Related Concept Videos
01:25Secondary Spinal Cord Injury llI: Pathophysiology
01:14Spinal Cord Injury ll: Pathophysiology